Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have earned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $17.30.

VIR has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday, December 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd.

Insider Buying and Selling at Vir Biotechnology

In related news, major shareholder Endurance (Cayman) Ltd Svf sold 466,242 shares of the stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $6.05, for a total transaction of $2,820,764.10. Following the completion of the sale, the insider owned 15,621,369 shares of the company’s stock, valued at approximately $94,509,282.45. This represents a 2.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 2,485,369 shares of company stock valued at $15,238,859. Insiders own 16.00% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

Several institutional investors have recently bought and sold shares of VIR. Raymond James Financial Inc. acquired a new stake in shares of Vir Biotechnology in the second quarter worth $35,000. FNY Investment Advisers LLC purchased a new stake in Vir Biotechnology during the 3rd quarter worth $38,000. Federated Hermes Inc. boosted its position in Vir Biotechnology by 153.8% during the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares during the period. Apollon Wealth Management LLC acquired a new stake in Vir Biotechnology in the 2nd quarter valued at $50,000. Finally, Daiwa Securities Group Inc. raised its position in Vir Biotechnology by 2,200.6% in the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after purchasing an additional 11,773 shares during the period. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across multiple quarters and fiscal years (Q4 2025, Q1–Q4 2026, FY2025–FY2029), trimming expected losses (FY2026 now -$2.16 vs prior -$2.40) and kept a Buy rating and $15 target — this suggests analysts see improving operating trends and provides a bullish price benchmark. MarketBeat: VIR coverage
• Neutral Sentiment: The upgrades narrow projected losses but consensus still implies multi‑year negative EPS (current consensus ~-3.92 FY). The changes signal gradually improving expectations rather than an immediate profitability inflection. MarketBeat: VIR coverage
• Negative Sentiment: Fundamentals remain a constraint: Vir missed Q3/Q4 earnings (Nov. 5) with a larger-than-expected loss and very low revenue ($0.24M), negative margins and negative ROE — these factors, plus limited near‑term commercial revenue and ongoing R&D spend, are likely keeping the stock under pressure. MarketBeat: VIR coverage

Vir Biotechnology Price Performance

NASDAQ VIR opened at $5.94 on Monday. The company has a market cap of $826.37 million, a P/E ratio of -1.65 and a beta of 1.39. Vir Biotechnology has a 12 month low of $4.16 and a 12 month high of $14.45. The company has a 50-day moving average of $5.99 and a 200-day moving average of $5.53.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $1.98 million. Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. Vir Biotechnology’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.56) earnings per share. As a group, equities research analysts anticipate that Vir Biotechnology will post -3.92 EPS for the current year.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.